Portfolio Companies News
August 23, 2017Nordic Nanovector ASA – Results f...
All operations on track, strong data presented at ICML confirm Betalutin®’s promising efficacy and safety profile in recurrent iNHL patients, pivotal Phase 2 study, PARADIGME to start in 2H 2017 Oslo, Norway, 23 August 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the secon... read more
August 21, 2017Altimmune Submits Investigational N...
60 volunteers to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the... read more
August 17, 2017Altimmune Announces $14.7 Million S...
GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors to sell an aggregate of 15,656 shares of Series B convertible... read more
August 17, 2017MIPS: INTERIM REPORT JANUARY – JU...
APRIL – JUNE Net sales increased by 55% to MSEK 36.6 (23.6) Operating profit rose to MSEK 11.0 (5.6). Adjusted operating profit* increased to MSEK 11.5 (7.4) Operating margin improved to 30.2% (23.7) Adjusted operating margin* increased to 31.5% (31.2) Cash flow from operating activi... read more
August 17, 2017BONESUPPORT - Q2 2017 Interim Repor...
Lund, Sweden, 08.00 CEST, 17 August 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT™ platform today publishes its Interim Report, J... read more
July 14, 2017Q2 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 108 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.